Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

The FDA issued an RTF for sBLA of nogapendekin alfa plus BCG for BCG-unresponsive NMIBC papillary disease, following prior ...

CG Oncology Inc.’s latest research effort to treat bladder cancer is impressing investors.The Irvine-based biopharmaceutical ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research ...

Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in ...

It is more likely to recur after treatment. There is also a greater risk of CIS developing into Muscle Invasive Bladder Cancer ("MIBC").9 7 Llano A, Chan A, Kuk C, Kassouf W, Zlotta AR. Carcinoma In ...

Photodynamic therapy using TLD-1433 represents a viable treatment option for BCG-unresponsive NMIBC CIS with an acceptable safety profile. Light-activated TLD-1433 photodynamic therapy (PDT) may ...

ImmunityBio's sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...

The RTF letter was unexpected, especially considering the positive feedback and unanimous encouragement ImmunityBio received ...

ImmunityBio, Inc.’s IBRX share price has dipped by 9.48%, which has investors questioning if this is right time to buy.

Minute Investor Podcast, where Stockhouse columnists Jonathon Brown and Trevor Abes each deliver a 2.5-minute stock pick ...